Development of topical microbicides for prevention of human immunodeficiency virus and herpes simplex virus
Keller, M.J.; Klotman, M.E.; Herold, B.C.
American Journal of Reproductive Immunology 49(5): 279-284
2003
ISSN/ISBN: 1046-7408 PMID: 12854732 DOI: 10.1034/j.1600-0897.2003.00044.xDocument Number: 263195
Topical microbicides, designed for vaginal or rectal administration, are needed to prevent human immunodeficiency virus (HIV) and other sexually transmitted infections (STI). Presently marketed topical microbicides are cytotoxic and damage the vaginal epithelium with frequent use. Rational development of new candidate compounds should build on knowledge of the pathways of microbial invasion. The establishment of assays and models that predict efficacy and safety is critical. Comprehensive pre-clinical evaluation of promising microbicides should include rigorous assessment of the effects of repeated application of topical agents on mucosal inflammatory cells, cytokines, and the genital tract virus population. These studies will lay the groundwork for future clinical trials.
Document emailed within 0-6 h
Related Documents
Herold, B.C.; Scordi-Bello, I.; Cheshenko, N.; Marcellino, D.; Dzuzelewski, M.; Francois, F.; Morin, R.; Casullo, V.Mas.; Anderson, R.A.; Chany, C.; Waller, D.P.; Zaneveld, L.J.D.; Klotman, M.E. 2002: Mandelic acid condensation polymer: novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry Journal of Virology 76(22): 11236-11244Cremer, K.; Wohlenberg, C.; Notkins, A.L.; Mackett, M.; Moss, B. 1985: Vaccinia virus recombinant that expresses the herpes simplex virus type 1 glycoprotein d gene protects mice against lethal challenge by herpes simplex virus type 1 or herpes simplex type 2 and the establishment of a latent ganglionic infection by herpes simplex virus type 1 Lerner, R A , R M Chanock And F Brown (Ed ) Vaccines 85: Molecular And Chemical Basis Of Resistance to Parasitic, Bacterial, And Viral Diseases; Meeting, 1983 Xxi+407p Cold Spring Harbor Laboratory: Cold Spring Harbor, N Y , Usa Illus Paper 169-174
Cremer, K.; Wohlenberg, C.; Notkins, A.L.; Mackett, M.; Moss, B. 1985: Vaccinia virus recombinant that expresses the herpes simplex virus type 1 glycoprotein d gene protects mice against lethal challenge by herpes simplex virus type 1 or herpes simplex type 2 and the establishment of a latent ganglionic infection by herpes simplex virus type 1 Lerner, R A , R M Chanock And F Brown (Ed ) Vaccines 85: Molecular And Chemical Basis Of Resistance to Parasitic, Bacterial, And Viral Diseases; Meeting, 1983 Xxi+407p Cold Spring Harbor Laboratory: Cold Spring Harbor, N Y , Usa Illus Paper 169-174
Toutous-Trellu, L.; Hirschel, B.; Piguet, V.; Schiffer, V.; Saurat, J-H.; Pechère, M. 2004: Treatment of cutaneous human papilloma virus, poxvirus and herpes simplex virus infections with topical cidofovir in HIV positive patients Annales de Dermatologie et de Venereologie 131(5): 445-449
Devi, K.M.; Devi, K.S.; Singh, N.B.; Singh, N.N.; Singh, I.D. 2008: Co-infection of herpes simplex virus (HSV) with human immunodeficiency virus (HIV) in women with reproductive tract infections (RTI) Journal of Communicable Diseases 40(3): 193-197
Devi, K.M.; Devi, K.S.; Singh, N.B.; Singh, N.N.; Singh, I.D. 2008: Co-infection of herpes simplex virus (HSV) with human immunodeficiency virus (HIV) in women with reproductive tract infections (RTI) Journal of Communicable Diseases 40(3): 193-197
Mmbaga, E.J.; Leyna, G.H.; Stray-Pedersen, B.; Klepp, K.-I. 2011: Herpes simplex virus type-2 and human immunodeficiency virus infections in a rural population in Kilimanjaro Tanzania East African Journal of Public Health 8(1): 28-32
Kolawole, O.M.; Amuda, O.O.; Nzurumike, C.; Suleiman, M.M.; Ikhevha Ogah, J. 2016: Seroprevalence and Co-Infection of Human Immunodeficiency Virus (HIV) and Herpes Simplex Virus (HSV) Among Pregnant Women in Lokoja, North-Central Nigeria Iranian Red Crescent Medical Journal 18(10): E25284
Mahiane, S.G.; Ndong Nguema, E.P.; Pretorius, C.; Auvert, B. 2010: Mathematical models for coinfection by two sexually transmitted agents: the human immunodeficiency virus and herpes simplex virus type 2 case Applied Statistics 59(4): 547-572
Kolawole, O.M.; Amuda, O.O.; Nzurumike, C.; Suleiman, M.M.; Ikhevha Ogah, J. 2016: Seroprevalence and Co-Infection of Human Immunodeficiency Virus (HIV) and Herpes Simplex Virus (HSV) Among Pregnant Women in Lokoja, North-Central Nigeria Iranian Red Crescent Medical Journal 18(10): E25284
Dada, A.J.; Ajayi, A.O.; Diamondstone, L.; Quinn, T.C.; Blattner, W.A.; Biggar, R.J. 1998: A serosurvey of Haemophilus ducreyi, syphilis, and herpes simplex virus type 2 and their association with human immunodeficiency virus among female sex workers in Lagos, Nigeria Sexually Transmitted Diseases 25(5): 237-242
Cheshenko, N.; Keller, M.J.; MasCasullo, V.; Jarvis, G.A.; Cheng, H.; John, M.; Li, J-Hua.; Hogarty, K.; Anderson, R.A.; Waller, D.P.; Zaneveld, L.J.D.; Profy, A.T.; Klotman, M.E.; Herold, B.C. 2004: Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread Antimicrobial Agents and ChemoTherapy 48(6): 2025-2036
Nagot, N.; Ouedraogo, A.; Konate, I.; Weiss, H.A.; Foulongne, V.; Defer, M.C.; Sanon, A.; Becquart, P.; Segondy, M.; Sawadogo, A.; Van de Perre, P.; Mayaud, P.; Bahembera, E.; Berthe, A.; Coulibaly, M.; Defer, M.-C.; Diallo, R.; Djagbare, D.; Konate, I.; Ky-Dama, F.; M'Boutiki, G.T.; Meda, N.; Millogo, I.; Ouedraogo, A.; Ouedraogo, D.; Rouet, F.ço.; Sanon, A.; Sawadogo, H.; Vallo, R.; Andonaba, J.-B.; Sawadogo, A.; Mayaud, P.; Weiss, H.A.; Nagot, N.; Becquart, P.; Foulongne, V.; Segondy, M.; Van de Perre, P. 2008: Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels Journal of Infectious Diseases 198(2): 241-249
Okuku, H.Selassie.; Sanders, E.J.; Nyiro, J.; Ngetsa, C.; Ohuma, E.; McClelland, R.Scott.; Price, M.A.; Graham, S.M. 2011: Factors associated with herpes simplex virus type 2 incidence in a cohort of human immunodeficiency virus type 1-seronegative Kenyan men and women reporting high-risk sexual behavior Sexually Transmitted Diseases 38(9): 837-844
Scordi-Bello, I.A.; Mosoian, A.; He, C.; Chen, Y.; Cheng, Y.; Jarvis, G.A.; Keller, M.J.; Hogarty, K.; Waller, D.P.; Profy, A.T.; Herold, B.C.; Klotman, M.E. 2005: Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action Antimicrobial Agents and ChemoTherapy 49(9): 3607-3615
Prober, C.G.; Sullender, W.M.; Yasukawa, L.L.; Au, D.S.; Yeager, A.S.; Arvin, A.M. 1987: Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections New England Journal of Medicine 316(5): 240-244
Langenberg, A. 2004: Interrupting herpes simplex virus type 2 transmission: the role of condoms and microbicides Herpes: the Journal of the Ihmf 11(Suppl 3): 147a-154a
Baker, D.A.; Gonik, B.; Milch, P.O.; Berkowitz, A.; Lipson, S.; Verma, U. 1989: Clinical evaluation of a new herpes simplex virus ELISA: a rapid diagnostic test for herpes simplex virus Obstetrics and Gynecology 73(3 Part 1): 322-325
Biesiadecka, A. 2000: Immunogenic activity of temperature sensitive mutation of herpes simplex virus type-1 in mono- and polyvalent conditions with different attenuated strains of virus. I. Analysis of humoral immunity induced by mutant temperature sensitive herpes simplex virus type-1 in monovalent systems Medycyna Doswiadczalna i Mikrobiologia 52(1): 81-88
Rudinger, R. 1993: Neues und Altes zu anogenitalen Herpes-simplex-Virus-Infektionen - New and old aspects of anogenital herpes simplex virus infections - New and old aspects of anogenital Herpes simplex virus infections University of Koln. Department of Dermatology. Dermatological Meeting 68(1): 20-23